Immune responses following Mycobacterium tuberculosis (Mtb) infection or vaccination 21 are frequently assessed by measuring T cell recognition of crude Mtb antigens, 22 recombinant proteins, or peptide epitopes. We previously showed that not all Mtb-23 specific T cells recognize Mtb-infected macrophages. Thus, an important question is 24 what proportion of T cells elicited by Mtb infection recognize Mtb-infected macrophages.
Introduction

38
The WHO estimates that 23% of the world's population is latently infected with 39 T cells recognizing Mtb-infected macrophages was generally higher than the frequency of 142 T cells that made IFN-g in response to 32a93-102 and TB10.44-11 epitopes (Fig.2f ). Although 143 the frequency of TB10.44-11-specific CD8 T cells tracked the frequency of MIME + CD8 T 144 cells, our prior work shows that TB104-11-specific CD8 T cells do not recognize Mtb-145 infected macrophages 4 . In conclusion, although the frequencies of CD4 and CD8 T cells 146 that recognize Mtb-infected macrophages increased over time, it was still a low 147 percentage of the total splenic or pulmonary T cells.
149
Lung T cells recognize Mtb-infected macrophages by a MHC-dependent manner
150
T cell activation results from TCR-mediated recognition of MHC-presented 151 peptides (i.e., cognate activation) or from cytokine-driven stimulation by a TCR-152 independent mechanism (i.e., noncognate activation) 14 . IL-12, which is produced by Mtb-153 infected macrophages, is a principal driver of noncognate activation 15 . To discriminate 154 between cognate and noncognate T cell activation, pulmonary CD8 T cells were cultured 155 with Mtb-infected WT (i.e., MHCI-sufficient) or K b D b-/-(i.e., MHCI -/-) macrophages. CD8 T 156 cell recognition of Mtb-infected macrophages was largely MHCI-restricted since there was 157 a 90% reduction in SFC in the absence of K b and D b (Fig.3a ). Furthermore, blocking 158 had no effect on CD8 T cell recognition of Mtb-infected macrophages (Fig.3b ).
159
To address the possibility of noncognate activation among CD4 T cells, we 160 cultured pulmonary CD4 T cells with Mtb-infected WT (MHCII-sufficient) or Ab1 -/-(MHCII -161 /-) macrophages. Surprisingly, only a 40-50% reduction in SFC frequency was seen when 162 CD4 T cells were cultured with Mtb-infected MHCII -/macrophages ( Fig.3c ). One 163 possibility is that these CD4 T cells were nonconventional T cells 16, 17 ; another possibility 164 is that these T cells were conventional T cells, but in the absence of MHC, their IFN-γ 165 production was driven by IL-12 produced by the infected macrophages 18, 19 . When CD4 T 166 cells were cocultured with Mtb-infected WT macrophages in the presence of blocking 167 antibodies to IL-12, no reduction in T cell activation was observed (Fig.3d ). However, when 168 CD4 T cells and MHCII -/-Mtb-infected macrophages were cultured in the presence of 169 blocking antibodies to IL-12, there was a significant reduction in the SFC compared to the 170 control groups (Fig.3b) . These data indicate that while IL-12 is sufficient for noncognate 171 activation of lung CD4 T cells to secrete IFN-γ, the majority of the CD4 T cell-response is 172 MHCII-restricted, and cognate activation of CD4 T cells does not require IL-12. In We next adapted the MIME assay to a flow cytometry-based assay. Lung T cells 178 from infected mice were used for the MIME assay and in parallel, were cultured with Mtb-179 infected macrophages and analyzed by intracellular cytokine staining (MIM-ICS). These 180 two different assays led to similar estimates of the frequencies of CD4 and CD8 T cells 181 that recognize Mtb-infected macrophages using IFN-g as a readout (Fig.4a, 4b ).
182
Interestingly, while nearly all IFN-γ-producing CD8 T cells expressed CD69, a significant 183 fraction of IFN-γ-producing CD4 T cells were CD69-negative ( Fig.4a ).
184
The frequencies of CD4 and CD8 T cells that recognized well-characterized class 185 II and class I MHC-restricted Mtb epitopes were compared using elispot and ICS using 186 uninfected macrophages, and tetramers. We detected 5.1% ESAT-63-17/I-A b tetramer + and 187 1.2% Ag85b240-254/I-A b tetramer + CD4 T cells, consistent with published frequencies 7, 20 .
188
After stimulation with the ESAT-63-17 and Ag85b240-254 peptides the total frequency of CD4
189
T cells producing IFN-γ measured by ICS was greater than the frequencies determined 190 using the tetramers (Fig.4c , left). Just as we observed a large population of CD69 -CD4 T 191 cells that produced IFN-γ in response to Mtb-infected macrophages, CD69 was also 192 absent from a large fraction of the CD4 T cells that produced IFN-γ after ESAT-6 193 stimulation ( Fig.4c, left; Supplementary Figure 1 ). In contrast, the frequency of ESAT-63-194 17-or Ag85b240-254-specific T cells measured by the elispot assay was lower than that 195 determined by tetramer staining or by ICS ( Fig.4c ). For CD8 T cells, we detected 3.9% 196 32a93-102/K b tetramer + and 26.6% TB10.44-11/K b tetramer + , respectively, consistent with 197 published frequencies 5, 21, 22 . In contrast to the results obtained for CD4 T cells, the 198 frequency of CD8 T cells that recognized 32a93-102 and TB10.44-11 based on ICS was 199 similar to the frequency determined using tetramers (Fig.4c, right) . Similar to the results
200
obtained with CD4 T cells, the frequency of antigen-specific T cells determined by the 201 elispot assay for 32a93-102 and TB10.44-11, was lower than the frequency determined using 202 ICS or tetramers.
204
CD4 and CD8 T cells differ in their ability to recognize Mtb-infected macrophages
205
Hypothetically, the aggregate of T cell recognition of individual Mtb antigens should 206 approach or be equivalent to the degree to which T cells recognize Mtb-infected 207 macrophages. To assess whether T cell recognition of Mtb antigens is similar to the 208 recognition of Mtb-infected macrophages, we took advantage of the megapool of 300 209 peptides (p300) representing 90 antigens, all of which are frequently recognized by human 210 CD4 T cells from healthy IGRA+ individuals 23 . We cocultured lung cells obtained from 211 mice that had been infected for four weeks with Mtb-infected macrophages, or with the 212 p300 megapool, and measured IFN-γ production by T cells. The CD4 T cell response was 213 skewed more towards the recognition of Mtb-infected macrophages than to the p300 214 megapool, indicating that some epitopes presented by Mtb-infected murine macrophages 215 are not represented in the p300 megapool. In contrast, the CD8 T cell response was 216 skewed towards the recognition of the p300 megapool ( Fig.5a ). Thus, CD8 T cells 217 recognize Mtb antigens that are either poorly presented or are not presented by Mtb-218 infected cells but are represented in the p300 pool (e.g., TB10.41-15). Compared to CD8 T 219 cells, a greater frequency of CD4 T cells recognized Mtb-infected macrophages, indicating 220 that CD4 T cells recognize Mtb-infected cells better than CD8 T cells at this time point 221 ( Fig.5a ).
222
The number of intracellular bacilli could contribute to the differences in CD4 and 223 CD8 T cell recognitions of infected macrophages. For example, a human CFP10-specific 224 CD8 T cell clone poorly recognizes Mtb-infected DC unless they are heavily infected 24 . To 225 determine whether the MOI affects polyclonal T cell recognition of macrophages, purified
226
CD4 and CD8 T cells from the lungs of infected mice were cultured with macrophages 227 infected using a range of MOI, and recognition was measured by MIM-ICS. CD4 T cells 228 readily recognized infected-macrophages, even at a low MOI, and recognition increased 229 at an MOI of 1.2 and plateaued at an MOI of 5.8 ( Fig.5b ). In contrast, there was little or no 230 recognition by CD8 T cells at a low MOI, although recognition increased significantly when 231 the MOI was increased to 5.8. (Fig.5b) . Thus, pulmonary CD4 T cells recognize Mtb-232 infected macrophages with greater sensitivity than CD8 T cells.
234
Quantifying T cells that recognize Mtb-infected macrophages after BCG vaccination
235
We hypothesize that a protective vaccine will elicit MIME + T cells. We measured 236 splenic T cell recognition of Mtb-infected macrophages after 4-5 weeks post-237 subcutaneous vaccination with BCG, the only approved vaccine in clinical use for TB.
238
Under these conditions, BCG elicited T cells that recognize Mtb-infected macrophages, 239 and more T cells recognized Mtb-infected macrophages than those that recognized the 240 Mtb epitopes Ag85b240-254, 32a93-102, TB10.44-11 or the 300 peptide megapool ( Fig.6a ).
241
The dose of BCG used in our studies conferred nearly a 1 log10 CFU reduction when 242 mice were challenged with Mtb nine months after vaccination ( Fig.6b ). This result conferred by BCG. Thus, the MIME could be a complementary approach to assess T 246 cell-based vaccine candidates. 
262
We developed the MIME to quantify T cells that recognize Mtb-infected 263 macrophages. A majority of infected myeloid cells from the lungs contain 1 -5 bacteria 264 per cell 12 . To mimic in vivo conditions, we used an effective median MOI of 5, which 265 resulted in infection of 70% of the macrophages without compromising their viability.
266
These were important considerations since bystander APC can present antigens 267 released from Mtb-infected cells or from dying cells, as described for DC 25, [27] [28] [29] [30] . We 268 hypothesized that there would be a discrepancy between the frequency of T cells that 269 recognize peptide epitopes versus Mtb-infected macrophages. Consistent with our 270 hypothesis, we found a minority of purified CD4 and CD8 T cells from the lungs of Mtb-271 infected mice recognized Mtb-infected macrophages, although the frequency was 272 sometimes higher, particularly during chronic infection. In our studies, >90% of the CD8 T cells capable of recognizing Mtb-infected macrophages were class I MHC-restricted.
274
The CD4 T cell response was more complicated. In the absence of class II MHC, IL-12 275 was sufficient to drive noncognate IFN-γ secretion by a subset of pulmonary CD4 T 276 cells. When IL-12 was blocked, we found that majority of the IL-12 driven-IFN-γ 277 secretion was abrogated, and >80% of the CD4 T cells were class II MHC-restricted. A 278 similar observation was made for IL-18, which can drive antigen-experienced CD4 T 279 cells to secrete IFN-γ following Salmonella infection 14, 18 . Our data show that WT Mtb-280 infected macrophages are recognized by CD4 T cells in the presence of a strong TCR 281 stimulus, and this recognition is independent of IL-12.
282
An important finding is that, based on our IFN-γ elispot assay, the combined 283 frequency of CD4 T cells recognizing Ag85b240-254 and ESAT-63-17, two epitopes known to 284 be presented by infected macrophages, accounts for only one third of the polyclonal CD4
285
T cells that recognize Mtb-infected macrophages. The case is even more extreme for CD8 286 T cells. It is unknown whether 32a93-102 is presented by Mtb-infected macrophages; but 287 TB10.44-11 is not 4 . Thus, fewer than 10% of the total CD8 T cells that recognize Mtb-288 infected macrophages can be accounted for by known epitopes. Consistent with these 289 observations, our MIM-ICS data strongly suggest that there are other epitopes for CD4 T 290 cells that recognize Mtb-infected macrophages but are not represented in the multi-291 peptide pool 300. Conversely, there are epitopes for CD8 T cells that may not be efficiently 292 presented by Mtb-infected macrophages but are overrepresented in the multi-peptide pool 293 300. The megapool was developed based on peptide recognition in humans, and thus the 294 different MHCs in human and mice likely also contribute to differences seen, a similar 295 peptide pool developed in mice is currently not available.
296
A limitation of the MIME is its focus on IFN-γ. Although IFN-γ is useful for 297 detecting Mtb-specific T cell responses, we recognize that under some conditions or in 298 some individuals, other cytokines (e.g., IL-2, IL-17, and TNF) may be produced by T 299 cells in the absence of IFN-γ. Fortunately, both the ELISPOT and ICS assays can be 300 modified to detect more than one cytokine. A second limitation is the focus on antigens 301 that are presented during the first 48 hours of in vitro infection. An interesting issue was 302 that the frequency of epitope-specific T cells differed between assays 21, 31, 32 . Key 303 differences in methodologies and the timing (see methods) make direct comparisons 304 difficult. Similar discrepancies between elispot and ICS assays were previously found for 305 the T cell response to protein antigens 32 . For the class II MHC-restricted peptide 306 epitopes, ICS led to a greater calculated frequency than tetramers or elispot, while for 307 the class I MHC-restricted epitopes, the frequency based on tetramer staining and ICS 308 were similar, and greater than that determined by the elispot assay. One possibility is 309 that the class II tetramers may inefficiently detect low affinity antigen-specific T cells, 310 which may be more sensitively detected by dodecamers 33 . Regardless, both the Mtb-311 infected macrophage ELISPOT and the Mtb-infected macrophage ICS assay yield 312 similar frequencies of IFN-γ-producing T cells that recognize Mtb-infected macrophages.
313
Other studies have shown that after in vitro expansion, human and murine CD8 T 314 cell lines recognize and kill Mtb-infected DC or macrophages 24, 34-37 . These studies have 315 been useful for characterizing antigen specificity and T cell function, but cannot deduce 316 the ex vivo frequency of T cells that recognize infected macrophages. Additionally, 317 macrophage phagosomes are more degradative compared to DC phagosomes, which 318 may lead to differences in antigen presentation 38, 39 . Limited information is available 319 concerning the capacity of ex vivo T cells to recognize Mtb-infected cells 24, [34] [35] [36] [37] [40] [41] [42] .
320
Barriers to these experiments include the low frequency of antigen-specific T cells in 
336
At the present time, we have no data to directly correlate MIME + T cells with 337 control of CFU in vivo, as we do in vitro 4 . Since direct CD4 T cell recognition of infected 338 APC is required for CFU control in vivo 8 , it is likely that MIME + CD4 and CD8 T cells 
359
The low frequency of MIME + T cells is consistent with Mtb using multiple 360 strategies to evade detection by the immune system 50 . We and others have proposed 
369
We envision that the MIME assay could be used to study immune evasion by Mtb 370 and study T cell recognition of Mtb-infected macrophages. For example, we previously 371 used a modified version of the MIME assay to show that iNKT cells recognized Mtb-372 infected macrophages, and the MIME assay could be applied to other T cell subsets 373 (e.g., unconventional T cells) 52 . Finally, as we believe that recognition of Mtb-infected 374 macrophages by vaccine-elicited T cells will be a prerequisite to protection, we expect 375 that the MIME assay could be used to assess T cell-based vaccine candidates as a complementary approach to immunogenicity studies or other approaches such as the 377 mycobacterial growth inhibition assay. 
416
Then, the plates were left at room temperature for 30 minutes to allow the macrophages 417 to become nonadherent. Macrophages were harvested by gently pipetting the cells, 418 followed by washing each well twice. The harvested cells were washed twice by 419 centrifugation at 1500 rpm for 5 minutes. Live, Mtb-infected or uninfected macrophages 420 were counted by Trypan blue exclusion of dead cells and used in MIME. To assess 421 actual MOI, a subset of the macrophages was lysed using a final concentration of 1%
422
Triton-X-100, serially diluted using 0.9% NaCl-0.02% Tween-80 and immediately plated 423 on 7H11 plates.
425
Mtb-infected macrophage ELISPOT:
426
Mtb-infected or uninfected macrophages resuspended in complete media without 427 antibiotics were aliquoted at 10 5 cells/well in an elispot plate that had been coated with 428 the IFN-g capture antibody and blocked with complete media as per manufacturer's 429 instructions. Mtb-infected macrophages were allowed to adhere for at least 1 h at 37 o C, 430 5% CO2, and then T cells were added to the macrophages at variable T cell:APC ratio.
431
Positive controls included and anti-CD3 and anti-CD28 condition, (each at 2 µg/ml).
432
Where indicated, single peptides (10 µM) or the peptide megapool 300 (2 µg/ml) were 433 added to uninfected macrophages prior to the addition of T cells. T cells were 434 coincubated with macrophages for 18-24 h, followed by cell lysis using deionized water, 435 incubation with detection antibody and development as per manufacturer's instructions.
436
The elispot insert was fixed with 1% paraformaldehyde in PBS for 1 h and then washed 437 3x with water. The ELISPOT insert was allowed to dry overnight, and single-color red 438 spots were enumerated using the CTL ImmunoSpot S5 Analyzer, software version 
481
E) The Mtb-infected macrophage ELISPOT (MIME) assay was performed by infecting 482 macrophages with H37Rv at an MOI of 4, for 18-24 h. A titrated number of C7 T cells 483 were mixed with polyclonal T cells (10 5 /well) from uninfected mice and added to Mtb-484 infected macrophages (10 5 /well). Where indicated, the ESAT-63-17 peptide was added to 485 the wells. The assay was performed as described in the "Methods".
486
F) The P25 T cell line was added to Mtb-infected macrophages, and the MIME assay 
612
For experiments involving pulmonary T cells, lungs were dissected from infected mice 613 after perfusion with RPMI 1640. Single cell lung suspensions were prepared by coarse 614 dissociation using the GentleMACS tissue dissociator (Miltenyi Biotec, Germany), 615 followed by digestion for 30 min at 37 o C in a shaker at 85 rpm with 300 U/ml of 616 Collagenase type IV in complete media. Samples were processed again using the 617 GentleMACS tissue dissociator, strained through a 70 µm filter, washed 1x with PBS and 618 then strained through a 40 µm filter. CD4 or CD8 T cells were labeled with CD4 L3T4 619 microbeads or CD8a Ly-2 microbeads, respectively, followed by positive selection though magnetic column using AutoMACS (Miltenyi Biotec, Germany). Where indicated,
621
CD90.2 beads were used for CD4 and CD8 T cell positive selection. T cells were 622 resuspended in complete media without antibiotics before use. Purity of the enriched T 623 cells was confirmed by surface staining for CD4, CD8 and CD3 and was greater than 624 90%.
626
For experiments involving splenic T cells, spleens from infected or vaccinated mice were 627 dissociated using a syringe and filtered through a 70 µm filter. Splenocytes were washed 628 1x with PBS and strained through a 40 µm filter. Polyclonal CD4 or bulk T cells (CD4 629 and CD8 T cells) were enriched using Mojosort negative selection kits for CD4 and CD3, 630 respectively. T cells were resuspended in complete media without antibiotics before use.
631
Purity of the enriched T cells was confirmed by surface staining and was greater than 632 90%.
633
634 T-cell lines:
635
C7 CD4 + T cells (specific for ESAT-6) and P25 CD4 + T cells (specific for Ag85b) have 636 been described previously 4 . Briefly, C7 or P25 cell lines were stimulated in vitro with 637 irradiated splenocytes pulsed with 10 µM peptide ESAT-63-17 (EQQWNFAGIEAAASA) or 638 Ag85b240-254 (FQDAYNAAGGHNAVF) in complete media containing IL-2 at 20 u/ml, in 639 the absence of antibiotics. After the initial stimulation, the T-cell cultures were split every 640 two days for 3-4 divisions and rested for at least three weeks post-initial stimulation 641 before use. After the initial stimulation, the cells were cultured in complete media 642 containing IL-2 and IL-7 and final concentrations of 20 U/ml and 10 ng/ml, respectively. T 643 cells were used between three -six weeks post-initial stimulation. Purity of C7 T cell line 644 was assessed by Vb10.
646
BCG vaccination:
647
Mice were vaccinated subcutaneously with a single dose of BCG strain SSI diluted in 648 0.04% Tween-80 in PBS. BCG strain SSI was generously provided by Dr. Christopher
649
Sassetti (University of Massachusetts Medical School). The BCG stocks used for 650 vaccination were previously frozen and thawed immediately before use, washed 2x with 651 0.04% Tween-80 in PBS and used at an average dose of 500,000 CFU/mouse in a final 652 volume of 200 µl. To confirm the dose, bacteria used for vaccination were plated on 653 7H10 plates. Splenic T cells were enriched at 4-5 weeks and used for the Mtb-infected 654 macrophage ELISPOT as described above. 
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